236 related articles for article (PubMed ID: 30022254)
1. Medication persistence and risk of fracture among female Medicare beneficiaries diagnosed with osteoporosis.
Liu J; Guo H; Rai P; Pinto L; Barron R
Osteoporos Int; 2018 Nov; 29(11):2409-2417. PubMed ID: 30022254
[TBL] [Abstract][Full Text] [Related]
2. Examining the Effect of Medication Adherence on Risk of Subsequent Fracture Among Women with a Fragility Fracture in the U.S. Medicare Population.
Keshishian A; Boytsov N; Burge R; Krohn K; Lombard L; Zhang X; Xie L; Baser O
J Manag Care Spec Pharm; 2017 Nov; 23(11):1178-1190. PubMed ID: 29083977
[TBL] [Abstract][Full Text] [Related]
3. Examining the treatment gap and risk of subsequent fractures among females with a fragility fracture in the US Medicare population.
Keshishian A; Boytsov N; Burge R; Krohn K; Lombard L; Zhang X; Xie L; Baser O
Osteoporos Int; 2017 Aug; 28(8):2485-2494. PubMed ID: 28536737
[TBL] [Abstract][Full Text] [Related]
4. The association of adherence to osteoporosis therapies with fracture, all-cause medical costs, and all-cause hospitalizations: a retrospective claims analysis of female health plan enrollees with osteoporosis.
Halpern R; Becker L; Iqbal SU; Kazis LE; Macarios D; Badamgarav E
J Manag Care Pharm; 2011; 17(1):25-39. PubMed ID: 21204588
[TBL] [Abstract][Full Text] [Related]
5. Association between osteoporosis treatment change and adherence, incident fracture, and total healthcare costs in a Medicare Advantage Prescription Drug plan.
Ward MA; Xu Y; Viswanathan HN; Stolshek BS; Clay B; Adams JL; Kallich JD; Fine S; Saag KG
Osteoporos Int; 2013 Apr; 24(4):1195-206. PubMed ID: 23100119
[TBL] [Abstract][Full Text] [Related]
6. Comparing clinical and economic outcomes of biologic and conventional medications in postmenopausal women with osteoporosis.
Hernandez I; Zhang Y
J Eval Clin Pract; 2015 Oct; 21(5):840-7. PubMed ID: 26059485
[TBL] [Abstract][Full Text] [Related]
7. Adherence to oral bisphosphonates and the risk of subtrochanteric and femoral shaft fractures among female medicare beneficiaries.
Wang Z; Ward MM; Chan L; Bhattacharyya T
Osteoporos Int; 2014 Aug; 25(8):2109-16. PubMed ID: 24846316
[TBL] [Abstract][Full Text] [Related]
8. Hip and other fragility fracture incidence in real-world teriparatide-treated patients in the United States.
Burge RT; Disch DP; Gelwicks S; Zhang X; Krege JH
Osteoporos Int; 2017 Mar; 28(3):799-809. PubMed ID: 28028555
[TBL] [Abstract][Full Text] [Related]
9. Persistence at 12 months with denosumab in postmenopausal women with osteoporosis: interim results from a prospective observational study.
Silverman SL; Siris E; Kendler DL; Belazi D; Brown JP; Gold DT; Lewiecki EM; Papaioannou A; Simonelli C; Ferreira I; Balasubramanian A; Dakin P; Ho P; Siddhanti S; Stolshek B; Recknor C
Osteoporos Int; 2015 Jan; 26(1):361-72. PubMed ID: 25236877
[TBL] [Abstract][Full Text] [Related]
10. Utilization of osteoporosis medication after a fragility fracture among elderly Medicare beneficiaries.
Yusuf AA; Matlon TJ; Grauer A; Barron R; Chandler D; Peng Y
Arch Osteoporos; 2016 Dec; 11(1):31. PubMed ID: 27696099
[TBL] [Abstract][Full Text] [Related]
11. Persistence, adherence, and medication-taking behavior in women with postmenopausal osteoporosis receiving denosumab in routine practice in Germany, Austria, Greece, and Belgium: 12-month results from a European non-interventional study.
Hadji P; Papaioannou N; Gielen E; Feudjo Tepie M; Zhang E; Frieling I; Geusens P; Makras P; Resch H; Möller G; Kalouche-Khalil L; Fahrleitner-Pammer A
Osteoporos Int; 2015 Oct; 26(10):2479-89. PubMed ID: 26018090
[TBL] [Abstract][Full Text] [Related]
12. Increased treatment persistence and its determinants in women with osteoporosis with prior fracture compared to those without fracture.
Jacob L; Dreher M; Kostev K; Hadji P
Osteoporos Int; 2016 Mar; 27(3):963-969. PubMed ID: 26519418
[TBL] [Abstract][Full Text] [Related]
13. Association of teriparatide adherence and persistence with clinical and economic outcomes in Medicare Part D recipients: a retrospective cohort study.
Hazel-Fernandez L; Louder AM; Foster SA; Uribe CL; Burge RT
BMC Musculoskelet Disord; 2013 Jan; 14():4. PubMed ID: 23281846
[TBL] [Abstract][Full Text] [Related]
14. Out-of-pocket drug costs and drug utilization patterns of postmenopausal Medicare beneficiaries with osteoporosis.
Conwell LJ; Esposito D; Garavaglia S; Meadows ES; Colby M; Herrera V; Goldfarb S; Ball D; Marciniak M
Am J Geriatr Pharmacother; 2011 Aug; 9(4):241-9. PubMed ID: 21616722
[TBL] [Abstract][Full Text] [Related]
15. Evaluation on the cost-effective threshold of osteoporosis treatment on elderly women in China using discrete event simulation model.
Ni W; Jiang Y
Osteoporos Int; 2017 Feb; 28(2):529-538. PubMed ID: 27581955
[TBL] [Abstract][Full Text] [Related]
16. Post-fracture pharmacotherapy for women with osteoporotic fracture: analysis of a managed care population in the USA.
Wilk A; Sajjan S; Modi A; Fan CP; Mavros P
Osteoporos Int; 2014 Dec; 25(12):2777-86. PubMed ID: 25112720
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of pharmacological fracture prevention for osteoporosis as prescribed in clinical practice in France, Germany, Italy, Spain, and the United Kingdom.
Svedbom A; Hadji P; Hernlund E; Thoren R; McCloskey E; Stad R; Stollenwerk B
Osteoporos Int; 2019 Sep; 30(9):1745-1754. PubMed ID: 31270592
[TBL] [Abstract][Full Text] [Related]
18. Long-term persistence with anti-osteoporosis drugs after fracture.
Klop C; Welsing PM; Elders PJ; Overbeek JA; Souverein PC; Burden AM; van Onzenoort HA; Leufkens HG; Bijlsma JW; de Vries F
Osteoporos Int; 2015 Jun; 26(6):1831-40. PubMed ID: 25822104
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of denosumab versus oral alendronate for elderly osteoporotic women in Japan.
Mori T; Crandall CJ; Ganz DA
Osteoporos Int; 2017 May; 28(5):1733-1744. PubMed ID: 28210776
[TBL] [Abstract][Full Text] [Related]
20. Denosumab utilization among older adults in Ontario: patient characteristics, persistence with therapy, and return to therapy after an extended gap.
Ban JK; Hao BB; McCarthy L; Guilcher SJT; Cadarette SM
Osteoporos Int; 2019 Sep; 30(9):1865-1872. PubMed ID: 31317248
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
